Date: November 03, 2026

To,
The Manager - Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051

SYMBOL: REMUS

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company held on Tuesday, November 03, 2026

In compliance with Regulations 30 and 33 read with Schedule III and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors ("the Board") of the Company at their Meeting held today i.e., Tuesday, November 03, 2026 has inter-alia, approved the following:

1. **Unaudited Financial Results of the Company**

   Unaudited Standalone and Consolidated Financial Results of the Company for the half year ended September 30, 2026, together with the Limited Review Report thereon;

   Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, the Company hereby confirms and declares that M/s. Pankaj R. Shah and Associates, Chartered Accountants (Firm Registration No. 107361W), Statutory Auditors of the Company have issued their Limited Review Reports on the Unaudited Standalone and Consolidated Financial Results of the Company for the half year ended September 30, 2026.

   The financial results along with the reports of the auditors of the Company are enclosed herewith as **Annexure-A**.

   Media Release in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the half year ended September 30, 2026 is enclosed as **Annexure -B**.

2. **Dividend**

   The Board has approved 01st Interim Dividend of Re.1.00/- (Rupee One only) per equity share of face value of Rs. 10/- (Rupees Ten only) each fully paid up for the Financial Year 2026-27. The record date for the purpose of payment of Interim Dividend will be Saturday, November 07, 2026.

Kindly note that the meeting of the Board of Directors of the Company commenced at 12:00 P.M. (IST) and concluded at 03:30 P.M. (IST).

You are requested to take the aforesaid information on your record.

Thanking you
For, Remus Pharmaceuticals Limited

DEVAL BAKULKUMAR PATEL
Digitally signed by DEVAL BAKULKUMAR PATEL
Date: 2026.11.03 15:53:44 +05'30'

Deval Patel
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Encl.: As above

Pankaj R Shah & Associates
Chartered Accountants

CA. DR. Pankaj Shah	CA. Chintan Shah	CA. Nilesh Shah	CA. Manali Shah	CA. Sandip Gupta
B.Com., F.C.A., Ph. D. (Commerce)	B.Com., L.L.B., F.C.A.	B.Com., L.L.B., F.C.A.	B.Com., F.C.A.	B.Com., F.C.A.

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. **URL : http://www.prsca.in**

Independent Auditors Review Report on Unaudited standalone financial results of Remus Pharmaceuticals Limited for the half year ended September 30, 2026 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to,
The Board of Directors,
REMUS PHARMACEUTICALS LIMITED
Ahmedabad.

We have reviewed the accompanying statement of unaudited standalone financial results of **REMUS PHARMACEUTICALS LIMITED** (the "company") for the Half year ended September 30, 2026 (The "statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (" Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 03-11-2026
Place: Ahmedabad

For, Pankaj R Shah & Associates
Chartered Accountants
Registration No.107361W



D.B.Shah

CA Dhrutik Shah
Partner
Membership No.137738
UDIN: 26137738JYNDFP5635

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, B/h. Ashok Vatika, Nr. Jayantilal Park BRTS, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF UNAUDITED STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026

(Rs. In Crore)

	Particulars	As at 30th September, 2026 (Unaudited)	As at 31st March, 2026 (Audited)
A	**ASSETS**		
1	**Non-current assets**		
(a)	Property, Plant and Equipment	4.93	5.60
(b)	Capital work-in-progress	-	-
(c)	Other Intangible assets	0.04	0.01
(d)	Intangible asset under development	0.08	0.06
(e)	Right to Use Assets	1.38	1.71
(f)	Financial Assets		
	Investments	479.76	279.78
	Loans	15.13	11.03
	Other Financial Assets	2.37	0.12
(g)	Deferred Tax Assets (net)	-	-
(h)	Other Non-Current Assets	-	-
		503.69	**298.31**
2	**Current assets**		
(a)	Inventories	1.89	2.75
(b)	Financial Assets		
	Investments	26.62	17.53
	Trade receivables	27.85	23.75
	Cash and cash equivalents	5.47	2.76
	Bank Balance other than above	-	-
	Loans	7.15	7.28
	Other Financial Assets	17.49	24.50
(c)	Current Tax Assets (Net)	-	-
(d)	Other current assets	6.48	5.06
		92.95	**83.63**
	TOTAL ASSETS	**596.64**	**381.94**
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
(a)	Share capital	11.78	11.78
(b)	Other Equity	499.04	313.93
		510.82	**325.71**
	Liabilites		
	Non-current liabilities		
(a)	Financial Liabilities		
	Borrowings	4.12	4.00
	Lease Liabilities	1.32	1.22
(b)	Provisions	0.73	0.62
(c)	Deferred tax liabilities (net)	61.23	32.67
(d)	Other Non-Current Liabilities	-	-
		67.40	**38.51**
2	**Current liabilities**		
(a)	Financial Liabilities		
	Borrowings	0.15	0.33
	Lease Liabilities	0.24	0.65
	Trade payables		
	(A) Total Outstanding dues of Micro Enterprises and Small Enterprises	1.28	2.32
	(B) Total Outstanding dues of creditors other than Micro Enterprises and small Enterprise	4.80	4.39
	Other Financial Liabilities	0.43	0.30
(b)	Other current liabilities	8.80	7.68
(c)	Provisions	1.47	0.55
(d)	Current Tax Liabilities (Net)	1.25	1.50
		18.42	**17.72**
	TOTAL EQUITY AND LIABILITIES	**596.64**	**381.94**

For Remus Pharmaceuticals Limited,

Arpit Shah
Managing Director
DIN:07214641

REMUS PHARMACEUTICALS LIMITED AHMEDABAD

Place: Ahmedabad
Date: November 3, 2026

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, B/h. Ashok Vatika, Nr. Jayantilal Park BRTS, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(Rs. in Crore except for EPS)

Sr No.	Particulars	Half Year Ended on			Year Ended
		30th September, 2026 (Unaudited)	31st March , 2026 (Audited)	30th September, 2025 (Unaudited)	31st March , 2026 (Audited)
I	Revenue from operations	62.08	47.14	46.85	93.99
II	Other income	4.42	4.04	2.80	6.84
III	**Total Income (I+II)**	**66.50**	**51.18**	**49.65**	**100.83**
IV	**Expenses**				
	Cost of materials consumed	-	-	-	-
	Purchases of stock-in-trade	26.31	21.54	19.75	41.29
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.86	(1.31)	0.68	(0.63)
	Employee benefits expenses	5.05	4.17	4.37	8.54
	Finance costs	0.27	0.37	0.21	0.58
	Depreciation & Amortisation expenses	1.18	1.46	1.29	2.75
	Other expenses	8.16	7.79	7.28	15.07
	Total Expenses (IV)	**41.83**	**34.02**	**33.58**	**67.60**
V	**Profit before extraordinary items and tax (III-IV)**	**24.67**	**17.16**	**16.07**	**33.23**
VI	Extraordinary item	-	-	-	-
VII	**Profit before tax (V-VI)**	**24.67**	**17.16**	**16.07**	**33.23**
VIII	**Tax expense:**				
	Current tax	5.59	4.29	4.36	8.65
	Deferred tax	0.27	0.19	(0.32)	(0.13)
IX	**Profit for the period (VII-VIII)**	**18.81**	**12.68**	**12.03**	**24.71**
X	**Other Comprehensive Income**				
	A (i) Items that will not be reclassified subsequently to profit or loss	194.93	31.29	38.29	69.58
	(ii) Income tax relating to items that will not be reclassified subsequently to profit and loss	(28.22)	(4.36)	(5.47)	(9.83)
	B (i) Items that will be reclassified subsequently to profit or loss	0.24	0.28	-	0.28
	(ii) Income tax relating to items that will be reclassified subsequently to profit and loss	(0.06)	(0.07)	-	(0.07)
	Total Other Comprehensive Income for the period	166.89	27.14	32.82	59.96
XI	**Total Comprehensive Income for the period (IX+X)**	**185.70**	**39.82**	**44.85**	**84.67**
XII	**Paid up Share capital** *(face value Rs 10 per share)*	11.78	11.78	11.78	11.78
XIII	**Other Equity**				313.93
XIV	**Earnings per share**				
	Basic & Diluted	15.96	10.75	10.21	20.96
	(EPS not annualized for the half yearly ended period)				

For Remus Pharmaceuticals Limited,

Arpit Shah
Managing Director
DIN:07214641

Place: Ahmedabad
Date: November 3, 2026

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, B/h. Ashok Vatika, Nr. Jayantilal Park BRTS, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF UNAUDITED STANDALONE CASH FLOW FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026


(Rs. In Crore)

	Particulars	Half Year Ended	
		30th September, 2026 (Unaudited)	30th September, 2025 (Unaudited)
(A)	**Cash Flow from Operating Activities :**		
	Net Profit before Tax	**24.67**	**16.07**
	Adjustments for :		
	Depreciation & Amortisation expenses	1.18	1.29
	Interest Income	(1.49)	(1.23)
	Loss/(Gain) on Investments	(3.07)	(0.10)
	Finance Cost	0.20	0.13
	Interest on Lease Liability	0.07	0.08
	Operating cash flow Before Working Capital Changes	**21.56**	**16.24**
	Adjustments for:		
	Adjustements for Decrease/(Increase) in:		
	Other Current Assets	(1.42)	1.56
	Other Financial Assets	(0.09)	-
	Trade Receivables	(4.10)	(11.02)
	Inventories	0.86	0.68
	Other Non-Current Assets	-	0.01
	Adjustements for Decrease/(Increase) in:		
	Trade Payables	(0.63)	3.60
	Provisions	0.98	0.32
	Other Current & Non-Current Liabilities	0.53	(0.11)
	Other Financial Liabilities	0.13	0.06
	Cash Generated from/(used in) Operating Activities	**17.82**	**11.34**
	Direct Taxes Paid (Net)	(5.83)	(2.62)
	Net Cash from/(used in) Operating Activities (A)	**11.99**	**8.71**
(B)	**Cash Flow from Investing Activity :**		
	Purchase of property, plant and equipments, Capital Work in Progress, leasehold asset and other intangible assets	(0.23)	(3.06)
	Decrease/(Increase) in Loans	(3.97)	(1.78)
	Decrease/(Increase) in Fixed Deposits	5.26	4.40
	Disposal / (Purchase) of Investments	(11.67)	(13.08)
	Realised Loss/(Gain) on Investments	0.89	0.01
	Interest Received	1.09	1.23
	Net Cash from/(used in) Investing Activities (B)	**(8.63)**	**(12.28)**
(C)	**Cash Flow from Financing Activities :**		
	Proceeds /(Repayment) of Long Term Borrowings (Net)	0.10	2.02
	Proceeds /(Repayment) from Short Term Borrowings (Net)	(0.18)	(0.08)
	Increase/(Decrease) in Lease Liabilities	(0.32)	(0.28)
	Interest on Lease Liability	(0.07)	(0.08)
	Finance Cost Paid	(0.18)	(0.13)
	Net Cash Flow from/(used in) Financing Activities (C)	**(0.65)**	**1.45**
	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	**2.71**	**(2.12)**
	Add : Opening Cash & Cash Equivalents	2.76	3.46
	Closing Cash & Cash Equivalents	**5.47**	**1.34**

For Remus Pharmaceuticals Limited,



Arpit Shah
Managing Director
DIN:07214641



Place: Ahmedabad
Date: November 3, 2026

Remus Pharmaceuticals Limited

Registered office:1101 to 1103, 11th floor, South Tower, ONE 42, B/h. Ashok Vatika, Nr. Jayantilal Park BRTS, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 |Website: www.remuspharma.com | Phone: +91-79-29999857| E-mail: cs@remuspharma.com

Notes to Standalone Financial Results:

1. The above standalone unaudited financial results for the half year ended 30th September, 2026 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of Remus Pharmaceuticals Limited ("the Company") in their meetings held on 3rd November, 2026.

2. The above standalone unaudited financial results for the half year ended on 30th September, 2026 are prepared in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Accounting) Rules, 2014 as amended and other recognized accounting practices and policies, as applicable.

3. In accordance with Regulation 33 of the SEBI (LODR) Regulations 2015, the said standalone unaudited results have been reviewed by the Statutory Auditors of the Company for the half year ended on 30th September, 2026.

4. The Statement also includes the standalone unaudited financial results for the half year ended on 31st March, 2026 being the balancing figure between the standalone audited figures in respect of the full financial year ended 31st March, 2026 and the published unaudited year-to-date figures up to the half year of the previous financial year.

5. The Company operates in a single segment i.e. pharmaceutical product. Hence, the above financial results are based on single segment only.

6. The Company had issued bonus shares in the ratio of 1:1 i.e. 1 (one) new fully paid-up Equity Shares of Rs.10/- (Rupees Ten only) each for every 1 (One) existing fully paid-up Equity Share of Rs. 10/- (Rupees Ten only) each held by the shareholders as on the 'Record Date' i.e. 04th July, 2025.

7. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods. EPS has been adjusted to include the impact of Bonus issue of shares for the corresponding previous periods.

8. The Board of Directors of the company in their meeting dated 3rd November, 2026 have declared and approved the interim dividend of Rs 1/- (Rupee One only) per share for the FY 2026-27.

9. The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.

For, Remus Pharmaceuticals Limited,





Arpit Shah
Managing Director
DIN: 07214641

Date: November 03, 2026
Place: Ahmedabad

Pankaj R Shah & Associates
Chartered Accountants

CA. DR. Pankaj Shah	CA. Chintan Shah	CA. Nilesh Shah	CA. Manali Shah	CA. Sandip Gupta
B.Com., F.C.A., Ph. D. (Commerce)	B.Com., L.L.B., F.C.A.	B.Com., L.L.B., F.C.A.	B.Com., F.C.A.	B.Com., F.C.A.

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. **URL : http://www.prsca.in**

Independent Auditors Review Report on Unaudited Consolidated Financial Results of Remus Pharmaceuticals Limited for the Half year ended September 30, 2026 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,as amended

Review Report to,

The Board of Directors

REMUS PHARMACEUTICALS LTD
Ahmedabad.

We have reviewed the accompanying statement of unaudited consolidated financial results of **REMUS PHARMACEUTICALS LIMITED** (the "company") and its Subsidiaries (to gether the group) for the Half year ended September 30,2026. (the "statement") attached herewith, being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, as amended (the listing Regulation) .

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing obligations & Disclosure Requirements) Regulation,2015, (the Regulation) as amended, to the extent applicable.
The statement includes the results of the following entities

Parent Company/Holding Company :

i. REMUS PHARMACEUTICALS LIMITED

Subsidiaries :

i. RELIUS PHARMA SRL

ii. ESPEE GLOBAL HOLDINGS LLC
iii. RELIUS PHARMACEUTICALS LIMITADA
iv. ESPEE GLOBAL CLINICAL TRIAL SERVICES PRIVATE LIMITED

Stepdown Subsidiaries :

i. ESPEE BIOPHARAMA & FINE CHEM LLC

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (" Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

The Consolidated Financial Statements includes unaudited financial statements and other unaudited financial information in respect of 4 subsidiaries and 1 Step Down Subsidiary, whose financial statement reflect total assets of Rs 224.15 crores as at September 30, 2026, total revenues of Rs 553.15 crores,total net profit after tax (before consolidation adjustments) of Rs. 5.34 crores and net cash outflow of Rs 4.51 crores for the half year then ended on 30th September 2026. These unaudited financial statements and other unaudited financial information have been furnished to us as certified by the management. Our Opinion, in so far as it relates to amounts and disclosures included in respect of four subsidiaries and one Step Down Subsidiary, is based solely on the unaudited financial statements and other unaudited financial information given to us by the management.

Date: 03-11-2026
Place: Ahmedabad

For, Pankaj R Shah & Associates
Chartered Accountants
Registration No.107361W

PANKAJ R. SHAH & ASSOCIATES * CHARTERED ACCOUNTANTS * AHMEDABAD

D.B.Shah

CA Dhrutik Shah
Partner
Membership No.137738
UDIN: 26137738MLDGQG7485

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, B/H Ashok Vatika ,Nr. Jayantilal Park BRTS, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF CONSOLIDATED UNAUDITED BALANCE SHEET AS AT SEPTEMBER 30, 2026

(Rs. in Crore)

	Particulars	As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
A	**ASSETS**		
1	**Non-current assets**		
(a)	Property, Plant and Equipment	14.67	5.67
(b)	Capital work-in-progress	-	8.28
(c)	Goodwill	8.73	8.73
(c)	Other Intangible assets	0.25	0.02
(d)	Intangible asset under development	0.08	0.22
(e)	Right to Use Assets	3.28	3.85
(f)	Financial Assets		
	Investments	457.01	257.03
	Other Financial Assets	2.43	0.18
(g)	Deferred Tax Assets (net)	-	-
(h)	Other Non-Current Assets	0.02	0.03
		486.47	**284.01**
2	**Current assets**		
(a)	Inventories	74.52	72.06
(b)	Financial Assets		
	Investments	26.62	17.53
	Trade receivables	131.78	139.08
	Cash and cash equivalents	10.02	11.82
	Bank Balance other than above	0.71	1.06
	Loans	9.65	9.14
	Other Financial Assets	18.02	25.77
(c)	Current Tax Assets (Net)	-	-
(d)	Other current assets	29.80	18.20
		301.12	**294.66**
	TOTAL ASSETS	**787.59**	**578.67**
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
(a)	Share capital	11.78	11.78
(b)	Other Equity	524.00	339.21
		535.78	**350.99**
	Non-Controlling Interest	41.34	36.74
	Total Equity	**577.12**	**387.73**
2	**Liabilties**		
	Non-current liabilities		
(a)	Financial Liabilities		
	Borrowings	5.77	5.30
	Lease Liabilities	2.91	3.02
(b)	Provisions	0.73	0.62
(c)	Deferred tax liabilities (net)	60.60	32.51
(d)	Other Non-Current Liabilities	-	-
		70.01	**41.45**
	Current liabilities		
(a)	Financial Liabilities		
	Borrowings	16.18	17.37
	Lease Liabilities current	0.62	1.01
	Trade payables		
	(A) Total Outstanding dues of Micro Enterprises and Small Enterprises	1.30	2.38
	(B) Total Outstanding dues of creditors other than Micro Enterprises and small Enterprise	72.75	73.66
	Other Financial Liabilities	0.64	0.92
(b)	Other current liabilities	39.80	45.69
(c)	Provisions current	2.01	1.85
(d)	Current Tax Liabilities (Net)	7.16	6.61
		140.46	**149.49**
	TOTAL EQUITY AND LIABILITIES	**787.59**	**578.67**

For Remus Pharmaceuticals Limited

Ashah

Arpit Shah
Managing Director
DIN:07214641

REMUS PHARMACEUTICALS LIMITED AHMEDABAD

Place: Ahmedabad
Date: November 03, 2026

REMUS PHARMACEUTICALS LIMITED

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, B/H Ashok Vatika ,Nr. Jayantilal Park BRTS, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED ON SEPTEMBER 30, 2026

(Rs. in Crore except for EPS)

Sr No.	Particulars	Half Year Ended on			Year Ended
		September 30, 2026 (Unaudited)	March 31, 2026 (Audited)	September 30, 2025 (Unaudited)	As at March 31, 2026 (Audited)
I	Revenue from operations	614.12	453.43	400.20	853.63
II	Other income	4.14	3.77	2.93	6.69
III	**Total Income (I+II)**	**618.26**	**457.20**	**403.13**	**860.33**
IV	**Expenses**				
	Cost of materials consumed				
	Purchases of stock-in-trade	556.91	360.74	401.97	762.71
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2.47)	31.92	(52.43)	(20.50)
	Employee benefits expenses	8.02	6.60	6.22	12.82
	Finance costs	0.76	0.81	0.65	1.47
	Depreciation & Amortisation expenses	1.54	1.47	1.29	2.76
	Other expenses	21.73	24.39	17.53	41.92
	Total Expenses (IV)	**586.49**	**425.93**	**375.23**	**801.16**
V	**Profit before extraordinary items and tax (III-IV)**	**31.77**	**31.27**	**27.90**	**59.16**
VI	Extraordinary item	-	-	-	-
VII	**Profit before tax (V-VI)**	**31.77**	**31.27**	**27.90**	**59.16**
VIII	**Tax expense:**				
	Current tax	7.30	6.65	6.63	13.28
	Deferred tax	(0.19)	0.03	(0.32)	(0.29)
IX	**Profit for the period (VII-VIII)**	**24.66**	**24.58**	**21.59**	**46.17**
X	**Other Comprehensive Income**				
	A (i) Items that will not be reclassified subsequently to profit or loss	194.93	31.26	38.32	69.58
	(ii) Income tax relating to items that will not be reclassified subsequently to profit and loss	(28.22)	(4.35)	(5.48)	(9.83)
	B (i) Items that will be reclassified subsequently to profit or loss	(1.32)	(0.51)	0.98	0.47
	(ii) Income tax relating to items that will be reclassified subsequently to profit and loss	(0.06)	(0.08)	0.01	(0.07)
	Total Other Comprehensive Income for the period	165.33	26.32	33.83	60.15
XI	**Total Comprehensive Income for the period (XIII+XIV)**	**189.99**	**50.90**	**55.42**	**106.32**
	Profit for the year attributable to				
	Owners of the Holding Company	21.76	19.49	17.50	36.99
	Non-Controling Interests	2.89	5.09	4.09	9.18
	Other Comprehensive Income attributable to				
	Owners of the Holding Company	163.61	25.69	33.62	59.31
	Non-Controling Interests	1.71	0.63	0.21	0.84
	Total Comprehensive Income attributable to				
	Owners of the Holding Company	185.38	45.18	51.12	96.30
	Non-Controling Interests	4.60	5.73	4.30	10.03
XVI	**Paid up Share capital** (*face value Rs 10 per share*)	11.78	11.78	11.78	11.78
XVII	**Other Equity**				339.21
XVIII	**Earnings per share**				
	Basic & Diluted	20.92	20.86	18.33	39.19
	(EPS not annualized for the half yearly ended period)				

For Remus Pharmaceuticals Limited,



Arpit Shah
Managing Director
DIN: 07214641

Place: Ahmedabad
Date: November 03, 2026

Remus Pharmaceuticals Limited

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, B/H Ashok Vatika ,Nr. Jayantilal Park BRTS, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24232GJ2015PLC084536 | Website: www.remuspharma.com | Phone: +91-79-29999857 | E-mail: cs@remuspharma.com

STATEMENT OF UNAUDITED CONSOLIDATED CASH FLOW FOR THE PERIOD ENDED ON SEPTEMBER 30, 2026

(Rs. In Crores)

	Particulars	For the Half Year Ended	
		September 30, 2026	September 30, 2025
(A)	**Cash Flow from Operating Activities :**		
	Net Profit before Tax	**31.77**	**27.90**
	Adjustments for :		
	Depreciation & Amortisation expenses	1.54	1.29
	Interest Income	(0.94)	(1.23)
	Dividend Income	-	-
	Interest expenses	0.61	0.65
	Loss / (Gain) on Investments	(2.84)	(0.01)
	Interest on Lease Liability	0.15	-
	Profit on account of translating financial statements of Foreign Subsidiaries	(1.56)	1.02
	Provision for Employee Benefits - Remeasurement of Defined Benefit Obligations	-	(0.09)
	Operating Cash Flow before Working Capital Changes	**28.72**	**29.52**
	Movement in working capital		
	Adjustments for decrease/ (increase) in :		
	Trade Receivables	7.30	(39.64)
	Inventories	(2.46)	(53.97)
	Other Current Assets	(11.60)	(1.52)
	Other Non-Current Assets	-	0.01
	Other Financial Assets	(0.09)	-
	Adjustments for (decrease)/ Increase in :		
	Trade Payables	(2.00)	53.75
	Other Financial Liabilities	0.06	(0.01)
	Other Current & Non-Current Liabilities	(5.88)	25.02
	Provisions	0.29	0.45
	Cash Generated from/(used in) Operating Activities	**14.34**	**13.61**
	Direct Taxes Paid (Net)	(6.78)	(3.87)
	Nat Cash from Operating Activities (A)	**7.56**	**9.74**
(B)	**Cash Flow from Investing Activity :**		
	Purchase of property, plant and equipments, Capital Work In Progress, leasehold asset and other Intangible assets	(2.31)	(3.31)
	Proceeds from Sale of Property, Plant & Equipment	-	
	Decrease/(Increase) in Loans	(0.50)	8.07
	Decrease/(Increase) in Fixed Deposits	5.21	4.40
	Dividend Received	0.36	-
	Disposal / (Purchase) of Investments	(11.08)	(13.07)
	Interest Received	1.32	1.23
	Net Cash form Investing Activities (B)	**(7.00)**	**(2.68)**
(C)	**Cash Flow from Financing Activities :**		
	Proceeds /(Repayment) of Long Term Borrowings (Net)	0.47	2.07
	Proceeds /(Repayment) from Short Term Borrowings (Net)	(1.19)	(8.76)
	Interest on Lease Liabilities	(0.15)	
	Increase/(Decrease) in Lease Liabilities	(0.49)	(0.28)
	Dividend Paid	(0.06)	-
	Interest Paid	(0.94)	(0.65)
	Net Cash Flow from/(used in) Financing Activities (C)	**(2.36)**	**(7.62)**
	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	**(1.79)**	**(0.56)**
	Add : Opening Cash & Bank Balances	11.82	7.23
	Closing Cash & Bank Balances	**10.02**	**6.67**

For Remus Pharmaceuticals Limited

Arpit Shah
Managing Director
DIN: 07214641

Place: Ahmedabad
Date: November 03, 2026

Remus Pharmaceuticals Limited

Registered office: 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad Gujarat, India 380054

CIN: L24232GJ2015PLC084536 |Website: www.remuspharma.com | Phone: +91-79-29999857| E-mail: cs@remuspharma.com

Notes to Consolidated Financial Results:

1. The above consolidated unaudited financial results for the half year ended on September 30, 2026 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of Remus Pharmaceuticals Limited ("the Company") in their respective meetings held on November 03, 2026.

2. The above consolidated unaudited financial results for the half year ended on September 30, 2026 are prepared in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies Accounting) Rules, 2014 as amended and other recognized accounting practices and policies, as applicable.

3. In accordance with Regulation 33 of the SEBI (LODR) Regulations 2015, the said consolidated results have been reviewed by the Statutory Auditors of the Company for the half year ended on September 30, 2026.

4. The Statement also includes the consolidated audited financial results for the half year ended on March 31, 2026 being the balancing figure between the consolidated audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the half year of the said financial year.

5. Below mentioned subsidiaries have been consolidated in the said financial results for the half year ended on September 30, 2026:

   i. Relius Pharma SRL (Bolivia)
   ii. Relius Pharmaceuticals Limitada (Guatemala)
   iii. Espee Global Holdings LLC (USA)
   iv. Espee Biopharma & Fine Chem LLC (Stepdown Subsidiary) (USA)
   v. Espee Global Clinical Trial Services Private Limited (India)

6. The Company operates in a single segment i.e. pharmaceutical product. Hence, the above financial results are based on single segment only.

7. The Company issued bonus shares in the ratio of 1:1 i.e. 1 (one) new fully paid-up Equity Shares of Rs.10/- (Rupees Ten only) each for every 1 (One) existing fully paid-up Equity Share of Rs. 10/- (Rupees Ten only) each held by the shareholders as on the 'Record Date' i.e. 04th July, 2025.

8. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods. EPS has been adjusted to include the impact of Bonus issue of shares for the corresponding previous periods.

9. The Board of Directors of the company in their meeting dated November 03, 2026 have declared and approved the interim dividend of Rs. 1/- (Rupee One only) per share for the FY 2026-27.

10. The figures of the previous period have been re-grouped or rearranged, wherever considered necessary.

For, Remus Pharmaceuticals Limited,

Arpit Shah
Managing Director
DIN: 07214641

REMUS PHARMACEUTICALS LIMITED
AHMEDABAD

Date: November 03, 2026
Place: Ahmedabad

Media Release

REMUS PHARMACEUTICALS LIMITED ANNOUNCES FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

November 03, 2026: Remus Pharmaceuticals Limited (NSE-SME: REMUS) announces its results for the half year ended September 30, 2026

Standalone Financial Performance:

H1 FY 27 vs H1 FY 26

Revenue from Operations
H1 FY 27: ₹ 62.08 Cr
H1 FY 26: ₹ 46.85 Cr
Growth: 32.51%

EBITDA
H1 FY 27: ₹ 21.70 Cr
H1 FY 26: ₹ 14.77 Cr
Growth: 46.92%

PAT
H1 FY 27: ₹ 18.81 Cr
H1 FY26: ₹ 12.03 Cr
Growth: 56.37%

H1 FY 27 vs H2 FY 26

Revenue from Operations
H1 FY 27: ₹ 62.08 Cr
H2 FY 26: ₹ 47.14 Cr
Growth: 31.69%

EBITDA
H1 FY 27: ₹ 21.70 Cr
H2 FY 26: ₹ 14.95 Cr
Growth: 45.15%

PAT
H1 FY 27: ₹ 18.81 Cr
H2 FY 26: ₹ 12.68 Cr
Growth: 48.33%

Consolidated Financial Performance:

H1 FY 27 vs H1 FY 26

Revenue from Operations
H1 FY 27: ₹ 614.12 Cr
H1 FY 26: ₹ 400.20 Cr
Growth: 53.45%

EBITDA
H1 FY 27: ₹ 29.93 Cr
H1 FY 26: ₹ 26.91 Cr
Growth: 11.22%

PAT
H1 FY 27: ₹ 24.66 Cr
H1 FY26: ₹ 21.59 Cr
Growth: 14.22%

H1 FY 27 vs H2 FY 26

Revenue from Operations
H1 FY 27: ₹ 614.12 Cr
H2 FY 26: ₹ 453.43 Cr
Growth: 35.44%

EBITDA
H1 FY 27: ₹ 29.93 Cr
H2 FY 26: ₹ 29.78 Cr
Growth: 0.50%

PAT
H1 FY 27: ₹ 24.66 Cr
H2 FY 26: ₹ 24.58 Cr
Growth: 0.32%

Note: Consolidated EBITDA and PAT were dragged in H1 FY 27 because of initial set up and operating cost of Espee GCTS, Bolivia and Guatemala subsidiaries.

Media Release

H1-FY 27 Business Highlights:

- Won tender of 24 products in Bolivia.
- In-licensed several new molecules for Mexico, Chile, Vietnam, and Peru, supported by bioequivalence (BE) studies, strengthening the anti-infective and anti-allergy portfolio.
- Peru: Got plant approved by Digemid. Currently filling 60+ products in Peru.
- Secured a direct government tender in Venezuela.
- Product Registration and Approval in Venezuela.
- Biological Products
- Got Approval of Semaglutide Tablets and Injections. Commercialization is planned soon.
- Executed supply orders for Rotigotine Patches in Venezuela and initiated filings in Venezuela and other markets, expanding the CNS portfolio. This is our second Patch launch in the market.
- In discussion to In-licensed several other Biosimilar products which will add to our portfolio.
- Received Trademarks and Brand Approvals of products in Dominican Republic. Planning the B2C launch of products soon.
- Introducing 5+ new brands to be marketed and sold in Guatemala under own label.

Management Comments:

Commenting on the results, Mr. Arpit Deepakkumar Shah, Managing Director of Remus Pharmaceuticals Limited said, "We are pleased with the progress achieved during H1 FY27, marked by strong business momentum and continued expansion across our international markets. During the period, we secured key tenders, received important product and manufacturing approvals, and expanded our portfolio through new product registrations and in-licensing initiatives across several geographies. Our progress in biologicals, CNS and specialty products, along with upcoming B2C launches in select markets, further strengthens our growth prospects. Going forward, we remain focused on expanding our global footprint, driving new business opportunities and building sustainable long-term growth." Subsidiaries which we have invested in last 6 months and 1 year will start contributing substantially to revenue and PAT going forward."

Financial Statements:

Results for the half year ended September 30, 2026, prepared under Ind AS, are available in the Investors section of our website https://remuspharma.com/

About Remus Pharmaceuticals Limited:

Remus Pharmaceuticals Limited (NSE-SME: REMUS) is engaged in exporting, marketing and distribution of finished formulations of pharmaceutical drugs as well as API (Active Pharmaceutical Ingredient). Having strong footprints in 40+ countries across the globe, Remus is involved in the sales of niche, specialized and critical care finished formulations. Along with it they are providing technical consultancy services to various distributors for preparation of reports on the dossiers of the products, to be registered by the said distributors in several countries.

Safe Harbor

This document includes certain forward-looking statements based on the current expectations and assumptions of the management of Remus Pharmaceuticals Limited and its subsidiaries ("Remus"). These statements are subject to various risks, uncertainties, and changes in economic, business, regulatory, technological, and market conditions, including exchange rate fluctuations and financing costs, which may cause actual results to differ materially from those expressed or implied. Remus, its directors, affiliates, and employees undertake no obligation to update, revise, or modify any forward-looking statements, whether as a result of new information, future events, or otherwise.

Follow Remus Pharmaceuticals Limited on LinkedIn: https://www.linkedin.com/company/remus-pharmaceuticals/

Contact Information:

Investor Relations Representative:	**Chief Financial Officer**
Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903-9500 Email: remus@valoremadvisors.com	Mr. Bhavik Shah Remus Pharmaceuticals Limited Email: ir@remuspharma.com